ORAL COMPOSITIONS WITH IMMUNOMODULATING EFFECT RELATIVELY TO NATURAL KILLER CELLS Russian patent published in 2022 - IPC A61K31/20 A61K31/201 A61K31/202 A61K31/23 A61P15/06 

FIELD: medicine.

SUBSTANCE: invention concerns a method for the treatment of repeated spontaneous abortions or repeated unsuccessful implantations in female patients who have 12% or more of NK peripheral blood cells among all peripheral blood cells of a patient, and/or where the cytotoxicity of NK peripheral blood cells of a patient is at least 10% higher than the average cytotoxicity of the control population of healthy women of reproductive age in the absence of reproductive failures, and who have given birth to at least one child. The method includes the administration of a composition that contains at least one saturated, at least one monounsaturated and at least one polyunsaturated long-chain fatty acid or its esters, where at least 50 wt.% of active ingredients in the composition, calculated as fatty acids, are long-chain fatty acids and their composite esters, while the composition is administered orally during from 15 to 70 days, and where the total amount of fatty acids or their composite esters administered per day is from 0.03 g/kg of body weight to 1 g/kg of body weight, calculated as fatty acids. At the same time, oral administration of the composition does not cause side effects that can be observed during intravenous administration of Intralipid®.

EFFECT: use of the method allows to reduce both the number and cytotoxicity of NK peripheral blood cells, and also provides a longer effect of reduction in the cytotoxicity of NK cells – 12-14 weeks after discontinuation of treatment compared to 6-9 weeks when using the known Intralipid®.

13 cl, 9 tbl, 4 ex